Brief: Ocumension Therapeutics Says It Got Positive Results From Phase III Clinical Trial Of OT-1001
02/03/2022 10:03
March 2 (Reuters) - Ocumension Therapeutics 1477.HK :
* PHASE III CLINICAL TRIAL OF OT-1001 (ZERVIATE) ACHIEVED
ITS
PRIMARY CLINICAL ENDPOINT, RECEIVED POSITIVE RESULTS
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application